Evotec Subsidiary Gets Contract With U.S. Defense Department for Orthopoxvirus Drugs
July 05 2023 - 2:57AM
Dow Jones News
By Cecilia Butini
A U.S.-based subsidiary of German biotechnology company Evotec
has won a contract with the Defense Department to develop drugs
targeting orthopoxviruses, a family of viruses that includes
smallpox and monkeypox, the company said Wednesday.
The contract, which was awarded to Seattle-based Just-Evotec
Biologics, is worth up to $74 million and includes the rapid
development of drug prototypes based on monoclonal antibodies. It
will support the Defense Department's Joint Program Executive
Office for Chemical, Biological, Radiological and Nuclear Defense,
the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 05, 2023 03:42 ET (07:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Evotec (TG:EVT)
Historical Stock Chart
From Apr 2024 to May 2024
Evotec (TG:EVT)
Historical Stock Chart
From May 2023 to May 2024
